On June 4, 2019 Horizon Therapeutics plc (Nasdaq: HZNP), reported that the company will participate in the following conference in June (Press release, Horizon Therapeutics, JUN 4, 2019, View Source [SID1234536875]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The JMP Securities Life Sciences Conference

Date: June 20, 2019
Presentation Time: 10 a.m. ET
Location: New York
The conference presentation will be webcast live and may be accessed by visiting Horizon’s website at View Source A replay of the webcast will be available for the event.

On JUne 4, 2019 Patrick Soon-Shiong, MD, Chairman and CEO of NantKwest (Nasdaq:NK), a leading clinical-stage, natural killer cell based therapeutics company reported a clinical data update in patients who have received off-the-shelf aNK and/or haNK natural killer cell therapy in combination with immunotherapeutic agents in advanced solid tumors (Press release, NantKwest, JUN 4, 2019, https://ir.nantkwest.com/news-releases/news-release-details/nantkwest-announces-durable-complete-responses-multiple-advanced?field_nir_news_date_value[min]=2019 [SID1234536874]). These results demonstrated durable complete responses in 5 out of 35 patients with highly refractory late stage cancers across multiple tumor types.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Data presented at the Jefferies Healthcare Conference demonstrated complete responses across phase I combination studies of aNK/haNK with or without N-803, ImmunityBio, Inc.’s IL-15 fusion superagonist in solid tumor cancer patients with highly refractory disease. ImmunityBio, Inc. (formerly known as NantCell, Inc.) is an affiliated company of NantKwest. These combinations enhance NK and T cell activity and proliferation, and resulted in 14% complete responses across multiple indications, while demonstrating positive safety profiles. In patients with highly refractory and relapsed diseases who have failed multiple rounds of standard-of-care therapy, the responses were durable.

All five patients with complete responses remain alive to date, ranging from 4 to 24 months from the onset of response.

"We are excited by the durable complete responses seen in patients with highly refractory disease safely treated with off-the-shelf haNK or aNK — to date over 511 infusions of haNK cell therapy have been administered, without any patient requiring hospitalization or resulting in cytokine release syndrome," said Patrick Soon-Shiong, M.D. "These early signals of efficacy have now provided us a pathway to the development of registration trials across triple negative breast cell and Merkel cell carcinoma."

In addition, Dr. Soon-Shiong also announced the FDA authorization of a trial utilizing the first in class CD19 T-haNK for treatment of refractory diffuse large B-Cell Lymphoma and the IND filing of the first in class PD-L1 T-haNK for refractory solid tumors.

For additional information please go to www.nantkwest.com.

On June 4, 2019 Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, reported that it will participate in two upcoming investor conferences (Press release, Halozyme, JUN 4, 2019, View Source [SID1234536873]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Goldman Sachs 40th Annual Global Healthcare Conference on Wednesday, June 12 at 1:40 p.m. ET / 10:40 a.m. PT in Rancho Palos Verdes, CA. Dr. Helen Torley, president and chief executive officer, will represent the company in a question and answer session.
The JMP Securities Life Sciences Conference on Wednesday, June 19 at 2:30 p.m. ET / 11:30 a.m. PT in New York, NY. Laurie Stelzer, senior vice president and chief financial officer, will represent the company in a question and answer session.
A live webcast of each session can be accessed through the "Investors" section of www.halozyme.com, and a recording will be made available for 90 days following each event. To access a live webcast, please visit Halozyme’s website approximately 15 minutes prior to the presentation to register and download any necessary audio software.

On June 4, 2019 Oncology Venture A/S ("OV" or "the Company") reported that an e-abstract has been published in Journal of Clinical Oncology – an ASCO (Free ASCO Whitepaper) Journal –, describing that DRP (Drug Response Prediction) is able to predict which breast cancer patients will be high likelihood responders to neoadjuvant (early) treatment with doxorubicin (Press release, Oncology Venture, JUN 4, 2019, View Source [SID1234536872]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Neoadjuvant treatment of breast cancer is an important remedy if the tumors are responding adequately. The current lack of adequate biomarker guidance results in many patients receiving chemotherapy without an efficient antitumor effect. The e-abstract in Journal of Clinical Oncology reports positive results from a study of Oncology Venture’s multigene mRNA-based technology for drug response prediction (DRP). DRP has been thoroughly validated in other settings, most recently in prediction of epirubicin – a sister molecule – efficacy in advanced breast cancer [1].

Based on analyses performed by the authors, it is concluded that DRP can predict which patients will be high likelihood responders to neoadjuvant doxorubicin. Modern multigene technologies may help assist clinicians in choosing between upfront surgery or neoadjuvant chemotherapy.

The e-abstract "Doxorubicin response prediction in neoadjuvant breast cancer therapy" can be accessed her

1. Buhl ASK, et al. (2018): Predicting efficacy of epirubicin by a multigene assay in advanced breast cancer within a Danish Breast Cancer Cooperative Group (DBCG) cohort: a retrospective-prospective blinded study. Breast cancer research and treatment. doi: 10.1007/s10549-018-4918-4.

For further information, please contact:

For investor inquiries
Ulla Hald Buhl, IR & Communications
E-mail: [email protected]
Telephone +45 21 70 10 49 For media inquiries
Thomas Pedersen, Carrotize PR & Communications

E-mail: [email protected]
Telephone +45 60 62 93 90

On June 4, 2019 Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, reported that the company will host a business update call on Tuesday, June 11, 2019 at 11:00 a.m. ET (Press release, Advaxis, JUN 4, 2019, View Source [SID1234536868]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

During the call, Advaxis’ senior management will review the company’s clinical development programs and recent financial results, and provide a general business update. The company intends to issue a news release summarizing financial results for the fiscal second quarter ended April 30, 2019 after market close on Monday, June 10, 2019.

The conference call and live audio webcast information is as follows:

WHEN: Tuesday, June 11, 2019 at 11:00 a.m. ET
DOMESTIC DIAL-IN: (844) 348-6133
INTERNATIONAL DIAL-IN: (631) 485-4564
CONFERENCE ID: 6199489
WEBCAST: ir.advaxis.com/events-presentations

For those unable to participate in the live conference call or webcast, a digital recording will be available beginning June 11, 2019 two hours after the completion of the call. To access the recording, please dial (855) 859-2056 (domestic) or (404) 537-3406 (international) and provide the operator with the conference ID: 6199489. In addition, an audio webcast will be archived on the Company’s website for a period of time at www.advaxis.com.